Alembic Pharmaceuticals is currently trading at Rs. 581.50, up by 34.55 points or 6.32% from its previous closing of Rs. 546.95 on the BSE.
The scrip opened at Rs. 547.35 and has touched a high and low of Rs. 595.00 and Rs. 547.35 respectively. So far 1,22,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 791.70 on 15-Jul-2015 and a 52 week low of Rs. 514.35 on 05-Feb-2016.
Last one week high and low of the scrip stood at Rs. 595.00 and Rs. 517.90 respectively. The current market cap of the company is Rs. 10,962.20 crore.
The promoters holding in the company stood at 74.13%, while Institutions and Non-Institutions held 12.92% and 12.96% respectively.
Alembic Pharmaceuticals' API Facilities i.e. API I and API II both located at Panelav have been successfully inspected by the USFDA between June 20, 2016 and June 29, 2016. The company did not receive any Form 483 observations.
Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification. The launch of this product will be based on the outcome of the ongoing litigation in the United States District Court for the District of Delaware with UCB. Alembic now has a total of 47 ANDA approvals (43 Final approvals and 4 tentative approvals) from USFDA.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |